Close

Sustainable Packaging: The Secret to Cutting Costs in the Pharmaceutical Industry

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Related stories

Managing Quality and Regulatory Risks in Pharmaceutical Technology Transfer

Technology transfer moves more than manufacturing instructions. It moves process knowledge, supplier dependencies, labeling requirements, packaging specifications, and the evidence needed to demonstrate control. For medical device manufacturers, including those supporting drug-device combination products, these interfaces can become recurring sources of compliance gaps during site transitions, acquisitions, and remediation. The central problem is often not a missing procedure. It is a quality system that allows connected activities to change independently. A label revision may be approved while packaging artwork, supplier instructions, or production-system data still reflect an obsolete version. Staying inspection-ready requires manufacturers to manage these dependencies as one controlled system. Why Compliance Gaps Keep Recurring Findings are treated as documentation defects Revising a procedure can resolve an immediate discrepancy without changing the behavior that caused it. If unclear decision rights, weak escalation, or ineffective training remain, the same failure may surface elsewhere. Corrective and preventive action should distinguish the observed finding from its underlying cause and establish how effectiveness will be demonstrated. Ownership is divided across connected functions Quality, Regulatory Affairs, labeling, packaging engineering, operations, suppliers, and digital-system owners often maintain separate workflows. Each team may complete its assigned task while an interface remains uncontrolled. For example, changing an instruction for use can affect packaging configuration, translations, technical documentation, inventory disposition, and release controls. Transitions expose unresolved weaknesses Acquisitions and site transfers can introduce conflicting procedures, incomplete knowledge transfer, or different assumptions about validated processes. Regulatory changes add further demands. When these events coincide with CAPA or change-control backlogs, teams may prioritize administrative closure over risk reduction. Without a coordinated impact assessment, local fixes can create new gaps downstream. Establish the Regulatory Baseline Inspection readiness starts with knowing which requirements apply to the product, activity, and market. Pharmaceutical, device, and combination-product obligations are not interchangeable; transfer planning should identify the applicable requirements rather than assume one quality framework covers every operation. According to FDA’s Quality Management System Regulation overview and FAQs, the QMSR became effective on February 2, 2026, incorporates ISO 13485:2016 by reference, and introduced the updated device inspection process under Compliance Program 7382.850. ISO 13485 certification does not exempt a manufacturer from FDA inspection or guarantee compliance with FDA requirements. For devices marketed in the European Union, Regulation (EU) 2017/745, Annex I, Section 23, provides the primary requirements for information supplied with devices, including labels and instructions for use. Teams should assess the applicable provisions alongside relevant language, product-specific, and market requirements. A labeling review should therefore evaluate required content and consistency with the device’s intended purpose and supporting documentation—not merely artwork accuracy. How to Identify the Real Gaps Begin with a cross-functional assessment that follows actual product and information flows. Select representative transfers, label changes, supplier changes, and CAPAs, then trace each from initiation through implementation and effectiveness review. Map dependencies: Identify affected specifications, suppliers, packaging components, systems, validation activities, and training. Compare records with practice: Check whether approved procedures match what operators and reviewers actually do. Test traceability: Follow a requirement through technical documentation, labeling, production instructions, and release evidence. Examine recurrence: Look for repeated deviations, reopened actions, overdue changes, and findings shared across sites. Assess capacity: Determine whether qualified owners have enough time and authority to complete corrective work. Prioritize gaps by potential patient or user harm, regulatory impact, likelihood of recurrence, and detectability. Document the rationale; an old overdue item is not automatically more important than a newly identified high-risk weakness. Align Quality, Labeling, Packaging, and Change Control Create a coordinated remediation plan with one accountable owner for each action, named contributors, acceptance criteria, and required evidence. Separate immediate containment from systemic correction. Containment might prevent obsolete labels from being issued; correction might redesign approval and implementation controls so obsolete versions cannot return. Use change control as the integration point. Before approval, evaluate effects on regulatory submissions or notifications, technical documentation, supplier controls, packaging performance, validation, electronic master data, inventory, and training. Record both identified impacts and justified decisions that particular activities are unaffected. During technology transfer, define readiness gates before production or release responsibilities move. These should address the transfer of process knowledge, acceptance criteria, receiving-site capability, required qualification or validation, approved documents, and personnel competence. The appropriate evidence depends on the product and process; a generic checklist cannot replace a documented assessment. Finally, verify implementation where the work happens. Confirm that current instructions are available, suppliers received approved requirements, systems contain correct versions, and affected personnel can perform their tasks. A signed approval is not evidence that every downstream change took effect. Mistakes That Undermine Inspection Readiness Closing CAPAs on task completion alone: Effectiveness checks should test whether the underlying failure has been controlled. Updating labels in isolation: Assess packaging, supplier, system, documentation, and inventory consequences. Counting closures instead of evidence: Dashboards need defensible records behind their status indicators. ...

State of API & Peptide CDMO Capacity

Pharmaceutical companies planning peptide or complex small-molecule launches are...

What Goes Into Synthetic Urine? The Chemistry Behind Replicating a Biological Fluid

Synthetic urine sounds simple until you look closely at...
- Advertisement -

Discover how sustainable packaging practices can help you reduce environmental impact and significantly cut costs.

Read on to uncover the connection between sustainability and profitability in switching to sustainable pharmaceutical packaging solutions starting today.

Understanding the Cost Implications of Traditional Packaging

Traditional packaging in the pharmaceutical industry often involves various types, such as plastics, glass, and metals. Each has cost implications, including the price of raw materials, the labor required for packaging, and the expenses related to waste management.

The choice of packaging can lead to increased costs in two ways. First, directly through the high prices of raw materials and labor. Second, indirectly due to inefficient waste management, which requires additional resources.

Thus, the costs linked with traditional packaging aren’t just financial but also environmental. Using unsustainable packaging materials contributes to waste and pollution. This inefficiency strains ecological resources and impacts the company’s bottom line. Hence, exploring sustainable packaging options is crucial to reduce environmental and economic costs.

The Concept of Sustainable Packaging

Sustainable packaging? What does it mean, exactly? Simply put, it’s an approach to packaging that considers the entire lifecycle of a product, from sourcing and production to disposal or reuse. It incorporates three core principles: effectiveness, efficiency, and life cycle.

Primarily, sustainable packaging ensures that the product is protected and preserved effectively. It considers the need for safe, reliable containment of pharmaceutical products to prevent contamination and maintain their efficacy.

Efficiency revolves around optimizing material and energy inputs. The goal is to do the job with less waste and reduced energy usage. This, in turn, means lower costs.

Finally, the cycle of life refers to a cradle-to-cradle perspective. The materials used should either be recyclable or compostable, which helps in waste management, another avenue for potential cost savings.

Sustainable packaging embraces materials like compostable plastics and FSC® certified materials. These materials reduce environmental impact and can be cost-effective in the long run. They embody the sweet spot where sustainability meets profitability, a key goal for any modern pharmaceutical company.

How Sustainable Packaging Cuts Costs

Let’s cut to the chase. How does sustainable packaging translate into cost savings? The magic ingredients are reduced material usage, minimized waste, and improved efficiency.

By design, sustainable packaging uses less material. Fewer resources mean less expense in purchasing raw materials. Considering that this saving applies to every item you package, the numbers start adding up fast.

Next, let’s talk about waste. Traditional packaging often leaves you with heaps of wasted material. These ‘leftovers’ are an environmental issue and a drain on your resources. Disposing of waste costs money. With sustainable packaging, waste is drastically reduced, easing pressure on your waste management budget.

Lastly, efficiency gets a boost with sustainable packaging. Modern, sustainable packaging solutions are often designed to be user-friendly and quickly assembled. This can lead to a significant reduction in labor costs, another plus on the balance sheet.

Sustainable packaging isn’t just good for the planet. It’s also good for your bottom line.

Steps to Transitioning to Sustainable Packaging

Now, if you’re wondering how to transition to sustainable packaging, here are a few steps.

Conduct a Packaging Audit: Examine your current packaging operations. Identify areas of waste, inefficiency, or high cost. It’s about discovering the ‘what’ and ‘why’ before moving to the ‘how.’

Research Sustainable Alternatives: Look for materials and designs that minimize environmental impact without sacrificing quality. Compostable plastics, FSC® certified materials, and post-consumer waste can be excellent alternatives.

Plan the Transition: This step involves calculating the costs and benefits of the switch. You’ll need to consider the initial investment, potential savings, and the expected ROI.

Implement New Designs: Replace your existing packaging with sustainable versions. Depending on your strategy and resources, it might be a gradual transition or an all-at-once approach.

Overcome Potential Barriers: Change can be challenging. Expect and plan for resistance, whether the cost of new equipment or the inertia of old habits.

It’s not an overnight process, but with each step, you’ll move towards a more sustainable – and cost-effective – future. Remember, the journey of a thousand miles begins with a single step.

The Role of Packaging Equipment in Sustainability and Cost-Savings

Choosing the right equipment is a crucial part of sustainable packaging. It’s like hiring the best team players – their performance can make or break the game.

Efficiency: Opt for machinery that promises high efficiency with low waste. Machines with low rejection rates and high-speed operations can save material and time.

Energy Consumption: Machines designed with energy conservation in mind reduce operating costs and carbon footprints. It’s a win-win situation for you and the planet.

Lifecycle Approach: Look for equipment manufacturers who adopt a lifecycle approach. These might offer machine rebuilds and rentals, extending the usable life of their products and reducing waste.

Smart Features: Modern machines come with smart features like automation and optimization. They can adapt to changes, prevent errors, and minimize waste.

Maintenance and Support: A breakdown can disrupt operations, causing delays and costs. Ensure your supplier offers reliable maintenance and support.

Making the right choice in packaging machinery is like setting the stage for a successful performance. It can significantly contribute to your sustainability goals and your bottom line. Choose wisely.

Like any great endeavor, it takes planning, effort, and time. Yet, the rewards are undeniable. Beyond cost savings, you gain a priceless reputation as a company that cares – about its products, people, and planet.

Start small. Take one step at a time. Gradually, sustainability will become second nature. The journey may be challenging, but the destination is worth it. A future where the environment thrives and your business prospers – that’s a vision worth striving for. So, are you ready to take the plunge?

Never miss a pharmaceutical headline

The pharmaceutical industry moves fast – stay on top of it with our must - read briefings.

  • The top pharma and life sciences stories, straight to your inbox
  • The biggest news, features, interviews, and analysis
  • Dedicated coverage of the key developments driving the global pharmaceutical sector

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Latest stories

Related stories

Managing Quality and Regulatory Risks in Pharmaceutical Technology Transfer

Technology transfer moves more than manufacturing instructions. It moves process knowledge, supplier dependencies, labeling requirements, packaging specifications, and the evidence needed to demonstrate control. For medical device manufacturers, including those supporting drug-device combination products, these interfaces can become recurring sources of compliance gaps during site transitions, acquisitions, and remediation. The central problem is often not a missing procedure. It is a quality system that allows connected activities to change independently. A label revision may be approved while packaging artwork, supplier instructions, or production-system data still reflect an obsolete version. Staying inspection-ready requires manufacturers to manage these dependencies as one controlled system. Why Compliance Gaps Keep Recurring Findings are treated as documentation defects Revising a procedure can resolve an immediate discrepancy without changing the behavior that caused it. If unclear decision rights, weak escalation, or ineffective training remain, the same failure may surface elsewhere. Corrective and preventive action should distinguish the observed finding from its underlying cause and establish how effectiveness will be demonstrated. Ownership is divided across connected functions Quality, Regulatory Affairs, labeling, packaging engineering, operations, suppliers, and digital-system owners often maintain separate workflows. Each team may complete its assigned task while an interface remains uncontrolled. For example, changing an instruction for use can affect packaging configuration, translations, technical documentation, inventory disposition, and release controls. Transitions expose unresolved weaknesses Acquisitions and site transfers can introduce conflicting procedures, incomplete knowledge transfer, or different assumptions about validated processes. Regulatory changes add further demands. When these events coincide with CAPA or change-control backlogs, teams may prioritize administrative closure over risk reduction. Without a coordinated impact assessment, local fixes can create new gaps downstream. Establish the Regulatory Baseline Inspection readiness starts with knowing which requirements apply to the product, activity, and market. Pharmaceutical, device, and combination-product obligations are not interchangeable; transfer planning should identify the applicable requirements rather than assume one quality framework covers every operation. According to FDA’s Quality Management System Regulation overview and FAQs, the QMSR became effective on February 2, 2026, incorporates ISO 13485:2016 by reference, and introduced the updated device inspection process under Compliance Program 7382.850. ISO 13485 certification does not exempt a manufacturer from FDA inspection or guarantee compliance with FDA requirements. For devices marketed in the European Union, Regulation (EU) 2017/745, Annex I, Section 23, provides the primary requirements for information supplied with devices, including labels and instructions for use. Teams should assess the applicable provisions alongside relevant language, product-specific, and market requirements. A labeling review should therefore evaluate required content and consistency with the device’s intended purpose and supporting documentation—not merely artwork accuracy. How to Identify the Real Gaps Begin with a cross-functional assessment that follows actual product and information flows. Select representative transfers, label changes, supplier changes, and CAPAs, then trace each from initiation through implementation and effectiveness review. Map dependencies: Identify affected specifications, suppliers, packaging components, systems, validation activities, and training. Compare records with practice: Check whether approved procedures match what operators and reviewers actually do. Test traceability: Follow a requirement through technical documentation, labeling, production instructions, and release evidence. Examine recurrence: Look for repeated deviations, reopened actions, overdue changes, and findings shared across sites. Assess capacity: Determine whether qualified owners have enough time and authority to complete corrective work. Prioritize gaps by potential patient or user harm, regulatory impact, likelihood of recurrence, and detectability. Document the rationale; an old overdue item is not automatically more important than a newly identified high-risk weakness. Align Quality, Labeling, Packaging, and Change Control Create a coordinated remediation plan with one accountable owner for each action, named contributors, acceptance criteria, and required evidence. Separate immediate containment from systemic correction. Containment might prevent obsolete labels from being issued; correction might redesign approval and implementation controls so obsolete versions cannot return. Use change control as the integration point. Before approval, evaluate effects on regulatory submissions or notifications, technical documentation, supplier controls, packaging performance, validation, electronic master data, inventory, and training. Record both identified impacts and justified decisions that particular activities are unaffected. During technology transfer, define readiness gates before production or release responsibilities move. These should address the transfer of process knowledge, acceptance criteria, receiving-site capability, required qualification or validation, approved documents, and personnel competence. The appropriate evidence depends on the product and process; a generic checklist cannot replace a documented assessment. Finally, verify implementation where the work happens. Confirm that current instructions are available, suppliers received approved requirements, systems contain correct versions, and affected personnel can perform their tasks. A signed approval is not evidence that every downstream change took effect. Mistakes That Undermine Inspection Readiness Closing CAPAs on task completion alone: Effectiveness checks should test whether the underlying failure has been controlled. Updating labels in isolation: Assess packaging, supplier, system, documentation, and inventory consequences. Counting closures instead of evidence: Dashboards need defensible records behind their status indicators. ...

State of API & Peptide CDMO Capacity

Pharmaceutical companies planning peptide or complex small-molecule launches are...

What Goes Into Synthetic Urine? The Chemistry Behind Replicating a Biological Fluid

Synthetic urine sounds simple until you look closely at...

Danaher Prepares to Introduce Advanced AI-Powered Laboratory

In a significant step for pharmaceutical research, Danaher has...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Translate »